AVDL:NSD-Avadel Pharmaceuticals plc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic | NASDAQ Global Market

Last Closing

USD 18.82

Change

+0.52 (+2.84)%

Market Cap

USD 0.43B

Volume

0.87M

Analyst Target

USD 17.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Avadel Pharmaceuticals PLC is a pharmaceutical company engaged in drug delivery and formulation development to create safer and more efficacious pharmaceutical products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

+0.38 (+0.27%)

USD 13.94B
VTRS Viatris Inc

-0.04 (-0.36%)

USD 13.29B
ITCI Intracellular Th

-1.53 (-2.30%)

USD 7.00B
LNTH Lantheus Holdings Inc

-1.43 (-1.76%)

USD 4.49B
ALKS Alkermes Plc

-0.31 (-1.27%)

USD 4.09B
ALVO Alvotech

N/A

USD 3.77B
HCM HUTCHMED DRC

-0.79 (-3.77%)

USD 3.23B
INDV Indivior PLC Ordinary Shares

-0.37 (-2.13%)

USD 2.44B
DCPH Deciphera Pharmaceuticals LLC

+0.01 (+0.04%)

USD 2.20B
AMPH Amphastar P

+0.74 (+1.73%)

USD 2.09B

ETFs Containing AVDL

QQQS Invesco NASDAQ Future Gen.. 0.80 % 0.00 %

-0.23 (-0.88%)

USD 8.10M

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 33.29% 84% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.29% 82% B 87% B+
Trailing 12 Months  
Capital Gain 25.80% 74% C 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.80% 74% C 76% C+
Trailing 5 Years  
Capital Gain 1,536.52% 100% F 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,536.52% 100% F 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 66.50% 94% A 93% A
Dividend Return 66.50% 94% A 93% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 130.87% 20% F 11% F
Risk Adjusted Return 50.81% 90% A- 81% B-
Market Capitalization 0.43B 92% A 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector